Vai al contenuto principale della pagina

Marine Compounds and Cancer 2020



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Autore: Honecker Friedemann Visualizza persona
Titolo: Marine Compounds and Cancer 2020 Visualizza cluster
Pubblicazione: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Descrizione fisica: 1 electronic resource (480 p.)
Soggetto topico: Medicine
Soggetto non controllato: apoptosis
fucoidan
hepatocellular carcinoma
reactive oxygen species
3-alkylpyridinium polymers
nicotine
nicotinic acetylcholine receptor
non-small cell lung carcinoma
melanoma
sinulariolide
proteomic
mitochondria
caspase cascade
marine fungus
sediment
anthranilic acid
Penicillium paneum
cytotoxicity
dibromotyrosine
mitochondrial dysfunction
oxidative stress
topoisomerase
epigonal organ
bonnethead shark
Jurkat
tumor cell line
hippuristanol
PEL
AP-1
STAT3
Akt
colorectal cancer
marine mollusc
brominated indoles
shrimp
chemoprevention
fatty acids
carotenoids
cancer
nanoparticle
osteosarcoma
lung metastasis
elisidepsin
lipid rafts
hydroxylated lipids
fatty acid 2-hydroxylase
cooperative binding
membrane permeabilization
marine organisms
polysaccharides
anticancer
anticarcinogenic
mechanisms of action
fumigaclavine C
anti-proliferation
mitochondrial pathway
anti-cancer
anti-proliferative
carotenoid
cell cycle arrest
fucoxanthin
azoxymethane
bioactive natural product
isatin
in vivo model
Marthasterias glacialis L.
palmitic acid
ER-stress
CHOP
Antibody Drug Conjugates (ADCs)
marine antitumor agents
clinical trials
approved antitumor agents
AD0157
angiogenesis
marine drug
pyrrolidinedione
secondary metabolites
cancer preventive
chemopreventive
trabectedin
plitidepsin
tumor-associated macrophages
tumor microenvironment
preclinical
anticancer immunity
antiangiogenesis
fascaplysin
cyclin-dependent kinase
small cell lung cancer
camptothecin
poly(ADP-ribose)-polymerase inhibitor
breast cancer
seaweed
therapeutic compounds
autophagy
marine drugs
autophagy inhibitors
autophagy inducers
macrolide
programmed cell death
energy stress
araguspongine C
c-Met
HER2
gemcitabine
pazopanib
phase I
safety
soft tissue sarcoma
pachastrissamine
jaspine B
carbocyclic analogue
sphingosine kinase inhibitor
molecular modeling
ET-743
DNA minor groove binder
soft tissue sarcoma
chemotherapy
bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane (BDDPM)
anti-metastatic activity
cell adhesion
β1-integrin
FAK
BEL-7402 cell
triterpene glycosides
sea cucumbers
antitumor activities
arrest of cell cycle
antibacterial
marangucyclines
deep-sea
Streptomyces sp. SCSIO 11594
LS-1
SNU-C5/5-FU
TGF-β signaling
carcinoembryonic antigen
kalkitoxin
Moorea producens
mitochondria toxin
VEGF
angiogenesis inhibitor
hypoxia-inducible factor-1
HIF-1
Lyngbya majuscula
marine metabolites
SZ-685C
nonfunctioning pituitary adenomas
Ecklonia cava
phlorotannins
dieckol
migration
sipholenol A
ABC transporter
multidrug resistance
P-gp/ABCB1
BCRP/ABCG2
MRP1/ABCC1
marine natural products
glioblastoma
xyloketal B
proliferation
TRPM7
marine compound
ribosomal protein genes
snoRNA
FAU
RPS30
SNORA62
evolution
Porifera
Penicillium brevicompactum
Brevianamide
Mycochromenic acid derivative
antifouling
Caribbean sponge
plakortide
endoperoxide
leukemia
multi-drug resistant leukemia
Sarcophyton ehrenbergi
soft coral
terpenes
cembranoids
cytotoxic activity
molecular docking
uveal melanoma
oxidative stress
virtual screening
Topo I inhibitor
low toxic
natural product
Ulva fasciata
selenium-containing polysaccharide-protein complex
pseudopterosin
NF-κB
p65
inflammation
cytokine release
IL-6
TNFα
MCP-1
glucocorticoid receptor
paulomycins
Micromonospora
antitumor
Cantabrian Sea-derived actinobacteria
puupehenones
sponges
antiangiogenic
antitumoral
porifera/sponge
cancer genes
molecular oncology
bromophenol
molecular mechanisms
cell cycle
PI3K/Akt
p38/ERK
ROS
human lung cancer
glycosaminoglycans
antiproliferative
heparan sulphate
gliotoxin
NSCLC
adriamycin resistance
Sepia ink polysaccharides
antitumour
chemosensitization
anticoagulation
sea anemone
drug discovery
endothelial cells
RGD motif
kunitz type inhibitor
prostate cancer
antioxidant
natural marine compounds
marine biotechnology
microalgae
marine sponges
Aeroplysinin
Isofistularin
pheochromocytoma and paraganglioma
metastasis
cancer progression
cell adhesion molecules
integrin β1
hypoxia
phycocyanin
non-small cell lung cancer
NF-κB signaling
marine-derived drugs
bioanalysis
chromatography
manzamine A
epithelial-mesenchymal transition
lung cancer
circulating tumor cells
signal transduction
cisplatin
Lampetra morii
buccal gland
cystatin F
anti-angiogenesis
cystatin superfamily
Antimicrobial peptide (AMP)
Tilapia piscidin 4 (TP4)
non-small cell lung cancer (NSCLC)
itampolin A
FBDD
p38α
novel inhibitor
tetracenomycin X
cyclin D1
proteasomal degradation
p38
c-JUN
λ-carrageenan
heparanase
anticoagulant
depolymerisation
cell migration
Aspergillus
naphthopyrones
endophytic fungus
Leathesia nana
mangrove-derived actinomycete
ansamycins
divergolides
apoptosis-inducing activity
actinomycin
EMT
invasion
low molecular weight fucoidan extract
N-Ras
neuroblastoma-rat sarcoma
Cancer
programmed cell death-ligand 1
programmed cell death-ligand 2
human sarcoma cell line (HT1080 cells)
human normal diploid fibroblast (TIG-1 cells)
chimera
chemical conjugation
anticancer agent
hybridization
α9-nicotinic acetylcholine receptors (nAChRs)
breast cancer cells
αO-conotoxin GeXIVA
targeted therapy
gorgonian
Leptogorgia
humulane sesquiterpenoids
anticancer activity
12-deacetyl-12-epi-scalaradial
HeLa cells
Nur77
MAPK/ERK pathway
Mycalin A
C15 acetogenins
synthetic analogues
antiproliferative activity
A375 and HeLa cell lines
polyoxygenated steroids
sponge
Haliclona gracilis
Thalassia testudinum
thalassiolin B
polyphenols
CYP1A1
benzo[a]pyrene
JNK1/2
natural products
synergism
A549 cells
cytoskeleton
P2X7 receptor
pollution
anti-angiogenic
gene expression
HSP90
inhibitor
Persona (resp. second.): DyshlovoySergey A
HoneckerFriedemann
Sommario/riassunto: The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.
Titolo autorizzato: Marine Compounds and Cancer 2020  Visualizza cluster
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910557339303321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui